Track topics on Twitter Track topics that are important to you
Celltrion’s supply chain and warehousing procedures ensure the safe storage of Remicade biosimilars as demand fluctuates across markets, the drugmaker says.
Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.
Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab (CT-P13) had "comparable efficacy and safety" to reference product Remicade inflix...
Michael JohnsenHospira, now a Pfizer company, entered into an agreement with Celltrion and Celltrion Healthcare in 2009 for several potential biosimilar products, including the recently-approved Infle...
Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson & Johnson (NYSE: JNJ) and Merck & Co (NYSE: MRK)...
Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute...
Pfizer and Celltrion still face patent questions – and a pesky launch notification issue – after the ground-breaking US approval of their biosimilar version of Janssen's Remicade.
Move over Zarxio, there's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a...